Innovation Pharmaceuticals Inc (IPIX)

[LitesOut]

The Financial results from Q4 aren't delaying the filing, it's subsequent events past Dec 31, 2020. Since he already knows the R&D costs that wouldn't delay the filing. The main focus should be on the reason Leo gave for the delay, not the quantitative change in Financial results. That's a clue in itself that Q4 2020 R&D expense was $6.2M vs only $2.6 M in Q4 2019. That's merely a breadcrumb though, that a Q4 saw significantly more spend most likely due to clinical trial preparation and would be expected.

The focus is on:
"...due to a delay experienced by the Registrant in preparing disclosure relating to recent developments regarding clinical trials for the Registrant’s lead drug compound, and in particular, developments on or around the filing due date relating to clinical trials in the United States and Russia."